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Letters
Are there long-term effects of extracorporeal
shockwave lithotripsy in paediatric patients?
Sir,
The authors have described very well the long-term
consequences of extracorporeal shockwave lithotripsy
(ESWL) in children and concluded that there was no eﬀect
of ESWL on renal growth or development of hypertension
or diabetes mellitus later in life [1].
Although, not USA Food and Drug Administration
approved, ESWL is a commonly used treatment option for
paediatric stone disease [2]. The long-term bio-eﬀects of
ESWL are still considered controversial, especially in the
paediatric population.
Various studies have been conducted in this regard, but the
dilemma persists as to whether ESWL given in the early
decades of life is harmful as regards the later development
of hypertension, diabetes mellitus or impact on renal
growth. These issues are of concern as several animal
studies have proved the potential for adverse long-term
consequences of ESWL in the paediatric population in the
form of a signiﬁcant decrease in eﬀective renal plasma ﬂow
or a signiﬁcant increase in mean arterial blood pressure [3].
These animal studies suggest that the acute renal injury
may progress to scar formation resulting in loss of
functional renal volume. Also in a 9-year follow-up study of
children, overall renal size was found to be decreased not
only in the treated kidney after a session of ESWL, but also
in the contralateral normal kidney [4].
There is ample published evidence that suggests the
development of new onset of diastolic hypertension in
adults long after lithotripsy and the paediatric kidney is
more susceptible to injury as compared with adults [5].
Nevertheless, there is the utmost need for further research
with longer follow-up durations on the mechanism and
consequences of shockwave renal injury, especially in
young populations.
Manish Garg, Apul Goel and Arvind Kumar
Department of Urology, King George Medical University,
Lucknow, India
References
1 El-Nahas AR, Awad BA, El-Assmy AM et al. Are there
long-term eﬀects of extracorporeal shockwave
lithotripsy in paediatric patients? BJU Int 2013; 111:
666–71
2 Krambeck AE, Lingeman JE. Clinical implications and
bioeﬀects of shock wave lithotripsy. AUA Update Series
2009: 28
3 Neal DE Jr, Harmon E, Hlavinka T, Morvant A,
Richardson E, Thomas R. Eﬀects of multiple
sequential extracorporeal shock wave treatments on
renal function: a primate model. J Endourol 1991; 5:
217–21
4 Lifshitz DA, Lingeman JE, Zafar FS, Hollensbe DW,
Nyhuis AW, Evan AP. Alterations in predicted growth
rates of pediatric kidneys treated with extracorporeal
shockwave lithotripsy. J Endourol 1998; 12: 469–75
5 Janetschek G, Frauscher F, Knapp R, Höﬂe G, Peschel
R, Bartsch G. New onset hypertension after
extracorporeal shock wave lithotripsy: age related
incidence and prediction by intrarenal resistive index.
J Urol 1997; 158: 346–51
Reply
Sir,
Extracorporeal shockwave lithotripsy (SWL) is the most
commonly used treatment for non-complex urinary calculi
in adults. In pediatric patients, there were concerns about
the possible harmful eﬀects of ESWL on the parenchyma of
growing kidneys. These concerns were assessed in animal
models. Kaji et al. [1] reported histological changes in renal
tubular and glomerular epithelium and interstitial cells in
immature rabbits after SWL. These changes were thought
to be the cause of an increase in arterial blood pressure
among tested rabbits. However, SWL in that study was
delivered directly to the renal parenchyma, which is
diﬀerent from clinical practice where SWL is delivered to
the stones. Moreover, Kaji et al. [1] noticed no signiﬁcant
reduction in renal function or renal growth after SWL in
immature rabbits.
On the other hand, clinical studies have proved that there
are no signiﬁcant long-term harmful eﬀects of SWL on
pediatric kidneys [2–3] and SWL did not statistically aﬀect
linear growth (body height) or renal function in the
pediatric population [4].
The concerns about the development of systemic diseases,
e.g. hypertension and diabetes, were studied in adults with
contradictory results. In pediatric patients, Lottmann et al.
[2] and Frick et al. [3] found that SWL was not associated
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with increased incidence of hypertension. Our study
proved the long-term safety of SWL for renal stones during
childhood because there were no harmful eﬀects on renal
growth, linear growth or development of hypertension or
diabetes [5].
The lesson learnt from these studies is that safe application
of SWL in children requires adequate targeting, low
energies and a limited number of shocks per session for
sparing the renal parenchyma any possible deleterious
eﬀects [2]. Although SWL was considered to be the method
of choice for managing renal stones in children of all ages
[6], more studies with long-term follow-up are required to
conﬁrm the safety of SWL in pediatric patients.
Ahmed R. EL-Nahas
On behalf of the authors
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De novo erectile dysfunction after anterior
urethroplasty: a systematic review and
meta-analysis
Sir,
We read this article [1] with interest regarding the
incidence of de novo erectile dysfunction (ED) after
anterior urethroplasty. The authors have tried to clear the
‘grey areas’ in anterior urethroplasty and ED. However, the
authors need to address some issues.We would like to
know the basis by which the authors calculated the
incidence of ED, as no clear cut universal deﬁnition for ED
was followed in the diﬀerent studies. Of a total 36 studies,
preoperative data about ED was only available in ﬁve
studies [457 patients (ª20%) out of the total 2323], so how
did the authors calculate that some patients developed de
novo ED, as their preoperative status was unknown. It also
needs to be clariﬁed at what time after surgery erectile
function was assessed and how the authors concluded that
there was a 1% incidence of ED. Moreover, the total
number of patients with ED was 165, which is 7.1 % of the
total 2323 patients.
Apul Goel, Kuldeep Sharma and Pradeep Sharma
Department of Urology, King George Medical University,
Lucknow, India
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Sir,
We appreciate the opportunity to provide additional
information about our article [1]. The questions you raise
point out some limitations of meta-analysis in general. In
this study, meta-analysis involves comparing studies with
heterogeneous deﬁnitions of erectile dysfunction (ED) and
variation in follow-up duration across studies.
The deﬁnition for ED diﬀered across studies and ranged
from new reports of ED postoperatively to a decline in
International Index of Erectile Function (IIEF) score.
Whether or not ED was self-reported, if all patients were
questioned about ED, or if a standardised questionnaire to
evaluate ED was used, is described for each study in
Table 1. In retrospective studies where patients were not
asked about erectile function in advance, new onset ED
after urethroplasty is self-reported and is subject to recall
bias. In meta-analysis, the most weight was given to studies
that prospectively questioned all patients about ED with a
standardised questionnaire.
The time frame by which ED was determined was not
provided in the methods for all studies included in our
meta-analysis. The prospective studies that evaluated ED
typically used a time frame of 6–18 months to evaluate
postoperative erectile function. The study follow-up time
frame is listed in Table 1.
Letters
© 2013 The Authors
BJU International © 2013 BJU International E425
Random eﬀects meta-analysis was used to calculate the
incidence of ED rather than simply dividing the number of
cases of ED by the total number of patients [2].
Sarah D. Blaschko and Benjamin N. Breyer
On behalf of the authors
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Newer and novel artificial urinary sphincters
(AUS): the development of alternatives to the
current AUS device
Sir,
Despite the growing emergence of mini-invasive surgical
treatments for urinary incontinence (i.e., urethral slings,
injections of bulking agents, adjustable continence therapies,
and stem cell therapies), the AMS 800® artiﬁcial urinary
sphincter (AUS) (American Medical Systems, Minnetonka,
MN, USA) has remained the ‘gold standard’ treatment for
stress urinary incontinence in men and women over the last
40 years. Despite the favourable outcome and satisfaction
rates after its implantation, this device continues to be
associated with the risk of local complications (i.e., atrophy,
erosion and infection) or mechanical failure. Thus, regular
revisions and/or explantations are mandatory in at least 30%
of AUS devices. New and more sophisticated AUS devices
have recently been developed to improve function,
occlusive eﬃciency, and biocompatibility relative to its
current design.
In a recent article, Chung et al. [1] provided a review of
new and/or innovative AUS devices.
The FlowSecure AUS (FlowSecureTM, RBM-Med) was
designed in 1991 with early functional outcomes reported
in 2006. It has the main advantage of instantly increasing
the pressure delivered to the urethra, only during stress
increases in intra-abdominal pressure.When deactivated,
the cuﬀ returns to the initial low pressure level, never
exceeding 40 cmH2O, thus minimising the risk of urethral
atrophy and/or erosion. As indicated by Chung et al.
[1], despite encouraging preliminary results with the
FlowSecureTM, more recent data have shown high
mechanical failure and infection rates, as well as risk of
pump assembly perforation in short- to intermediate-term
follow-up.
The Periurethral Constrictor (Silimed, Rio de Janeiro,
Brazil) was released in 1996. It is simple to use and of
low cost. However, there are only a few published
studies with controversial outcomes for the device in a
post-prostatectomy urinary incontinence setting [2]. The
routine use of this device is debatable.
The Tape Mechanical Occlusive Device (GT Urological
LLC, Minneapolis, MN, USA) is a non-hydraulic one-piece
device that is manually controlled by the patient through its
on/oﬀ buttons [3]. It has been implanted in dogs to assess
its function, occlusive eﬃciency, and biocompatibility and
in human male cadavers to assess its occlusive eﬃciency
and sizing, with encouraging results. Prospective clinical
studies are awaited.
Two additional devices have been developed in France. The
ZSI 375 (Zephyr Surgical Implants, France) was released in
2005 (http://zephyr-si.com/zephyr/index.php?lg=en.) and
has not yet been approved by the French Health Authority
Agency (http://www.has-sante.fr/portail/jcms/c_896387/
zsi-375-cnedimts-du-24-novembre-2009-2254) despite
publication of recent data. No strong basic (bench and
animal) and/or clinical data are available, and the use of
this device should be done under a prospective controlled
study before extensive use. Indeed, only a few preliminary
monocentric retrospective observational studies have been
reported. There are no favourable comparisons with the
AMS 800®, and as opposed to the two following devices, the
Versatile Automated Device and electromechanical device,
it has not followed, at least through published papers, the
usual process of validation.
Chung et al. [1] have not mentioned the Versatile
Automated Device recently designed by another French
team [4], designed to obtain a lower exerted pressure on
the urethral tissues and improve continence eﬃciency
according to the patient’s activity. In fact, this device
includes a sensor, which automatically detects
circumstances involving high bladder pressure and adapts
the occlusive pressure accordingly. The device was
evaluated using isolated goat urethra and, then, in vivo with
encouraging preliminary results. Research studies (bench
and animal) are still running and awaited.
An electromechanical device has also been developed by
Valerio et al. [5] and recently tested in animals. Its principle
is an electromechanical induction of alternating
compression of successive segments of the urethra by a
series of cuﬀs activated by artiﬁcial muscles. This ovine
study showed that this device could provide continence.
This new electronic-controlled sequential alternating
compression mechanism avoided damage to urethral
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vascularity for at least 3 months after implantation. After
this positive early step, long-term studies are needed before
clinical application can be considered. Table 1 shows the
innovative principles of each former model of the AUS.
In conclusion, in an era where AUS use is increasing, a new
and more sophisticated device is probably needed.
Whatever the use, in men or women, the AUS aims to
mimic continence/voiding phases as close as possible
to normal conditions. Nobody knows what the future
holds for hydraulic and mechanical devices. The
above-mentioned devices suggest that further studies are
required to assess the safety and eﬃcacy of these new
generation AUS devices, in comparison with the so-called
‘gold standard’ AMS 800®. The developmental steps for
these devices must include bench and animal studies, as
well as feasibility studies in humans to control for safety
and surgical eﬃciency. Figure 1 provides the main steps of
development of medical devices. After a feasibility study to
check the proof of concept, any clinical use must be
preceded by multicentre controlled studies. All of these
studies have to be done under ethical committee approval.
The recent USA Food and Drug Administration (FDA)
warning (http://www.fda.gov/MedicalDevices/
ProductsandMedicalProcedures/ImplantsandProsthetics/
UroGynSurgicalMesh/ucm262299.htm) about prolapse
Table 1 Innovative characteristics of AUS compared with the current AMS 800®.
Device More compact
than the
AMS 800®
Improved control
of pressure
during stress
Improved detection
of the administered
pressure
Adjustable Key remaining
questions
FlowSecure™ No Yes No Yes Pump perforation at
pressurisation
Periurethral Constrictor Yes No Yes Yes Controversial results on
continence
Tape Mechanical Occlusive
Device
Yes No No No but simplicity of use
with its on/oﬀ button
?
ZSI 375 Yes No No Yes No multicentre prospective
controlled study
Versatile Automated Device Yes Yes Yes Yes ?
Electromechanical Device ? Yes Yes No ?
Fig. 1 Key steps for the clinical development of a medical device.
Preclinical phase  Clinical phase Provision of the
medical device 
Research & development
to address the clinical
need  
In vitro tests
(biocompatibility tests) 
+/- Animal experiments
Pilot study 
Safety +++ (complication)
Selection of patients & 
surgical technique
Pivot Study
Main objective with Primary
endpoint 
Criteria of inclusion/exclusion
Choice of control treatment in
case of comparative study 
Experimental plane
Choice of investigating centres
(multicentre study)
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meshes in women should warn all clinical research teams
about the absolute need for careful evaluation for all new
implantable human devices.
Véronique Phé, Morgan Rouprêt and
Emmanuel Chartier-Kastler
AP-HP, Pitié-Salpêtrière Academic Hospital, Department of
Urology, Pierre et Marie Curie medical school, Paris 6
University, Paris France
References
1 Chung E, Ranaweera M, Cartmill R. Newer and novel
artiﬁcial urinary sphincters (AUS): the development of
alternatives to the current AUS device. BJU Int 2012;
110: 5–11
2 Schiavini JL, Damião R, de Resende Júnior JA,
Dornas MC, Cruz Lima da Costa DS, Barros CB.
Treatment of post-prostate surgery urinary
incontinence with the periurethral constrictor: a
retrospective analysis. Urology 2010; 75: 1488–92
3 Malaeb BS, Elliott SP, Lee J, Anderson DW, Timm
GW. Novel Artiﬁcial Urinary Sphincter in the Canine
Model: The Tape Mechanical Occlusive Device. Urology
2011; 77: 211–6
4 Lamraoui H, Bonvilain A, Robain G et al.
Development of a novel artiﬁcial urinary sphincter: a
versatile automated device. IEEE/ASME Transactions on
Mechatronics 2010; 15: 916–24
5 Valerio M, Jichlinski P, Dahlem R, Tozzi P, Mundy
AR. Experimental evaluation of an electromechanical
artiﬁcial urinary sphincter in an animal model. BJU Int
2013; 112: E337–43
Letters
© 2013 The Authors
E428 BJU International © 2013 BJU International
